Rubius Therapeutics, Inc. IPO Research Information

Rubius Therapeutics, Inc. IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on Rubius Therapeutics, Inc., and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
Rubius Therapeutics, Inc.	RUBY - NASDAQ	$20.00-$22.00	$23.00	$30.51	10.5 million	7/18/2018
Underwriter(s): J.P. Morgan, Morgan Stanley, Jefferies, Leerink Partners
Co-Manager(s):
Industry: Health Care
Filing(s): Filed 2018-06-22 Terms Added 2018-07-09

Rubius Therapeutics, Inc. Quote & Chart - Click for current quote - RUBY

About Rubius Therapeutics, Inc. (adapted from Rubius Therapeutics, Inc. prospectus):
They are pioneering the development of a new class of medicines, Red Cell Therapeutics, or RCTs.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as "RUBY" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.